Lingke
X

 

      +86 0571-87711179

ychen1@lynkpharma.com

Lynk Pharmaceuticals Co., Ltd.    |   浙ICP备19010130号-2   |   Powered by www.300.cn    |   Manager 

CONTACT US

website

Search

291 Fucheng Road, Bldg 5-402, Jianggan, Hangzhou,
Zhejiang 310018, China

Lynk Pharmaceuticals and Simcere announced Strategic Commercialization Partnership upon novel JAK1 inhibitor LNK01001
{{= $!info.name}}
On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. (Lynk Pharmaceuticals) and Simcere (2096.HK) announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor LNK01001 in China.
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Atopic Dermatitis
{{= $!info.name}}
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Ankylosing Spondylitis
{{= $!info.name}}
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Ankylosing Spondylitis
Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001
{{= $!info.name}}
Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001
Lynk Pharmaceuticals announced the completion of Series B financing of $50 million
{{= $!info.name}}
Lynk Pharmaceuticals announced the completion of Series B financing of $50 million
Lynk Pharmaceuticals Announced First Patient Dosed in Phase I Clinical Study of Its Triple-Kinase Inhibitor LNK01002
{{= $!info.name}}
Lynk Pharmaceuticals Announced First Patient Dosed in Phase I Clinical Study of Its Triple-Kinase Inhibitor LNK01002
上一页
1
2
3